These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 29402316)

  • 1. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
    Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM
    BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
    Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E
    Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase.
    Inoue M; Yoshimura M; Kobayashi M; Morinibu A; Itasaka S; Hiraoka M; Harada H
    Sci Rep; 2015 Oct; 5():15666. PubMed ID: 26503893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
    Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
    Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.
    Lieu CH; Klauck PJ; Henthorn PK; Tentler JJ; Tan AC; Spreafico A; Selby HM; Britt BC; Bagby SM; Arcaroli JJ; Messersmith WA; Pitts TM; Eckhardt SG
    Oncotarget; 2015 Oct; 6(33):34561-72. PubMed ID: 26439693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
    Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
    Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
    Valsasina B; Beria I; Alli C; Alzani R; Avanzi N; Ballinari D; Cappella P; Caruso M; Casolaro A; Ciavolella A; Cucchi U; De Ponti A; Felder E; Fiorentini F; Galvani A; Gianellini LM; Giorgini ML; Isacchi A; Lansen J; Pesenti E; Rizzi S; Rocchetti M; Sola F; Moll J
    Mol Cancer Ther; 2012 Apr; 11(4):1006-16. PubMed ID: 22319201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppression.
    Nair JS; Schwartz GK
    Cell Cycle; 2015; 14(19):3101-11. PubMed ID: 26236920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
    Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
    Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
    Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
    Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
    Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
    Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.
    Capasso A; Pitts TM; Klauck PJ; Bagby SM; Westbrook L; Kaplan J; Soleimani M; Spreafico A; Tentler JJ; Diamond JR; Arcaroli JJ; Messersmith WA; Eckhardt SG; Leong S
    Anticancer Drugs; 2018 Oct; 29(9):827-838. PubMed ID: 30048249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1).
    Nie Z; Feher V; Natala S; McBride C; Kiryanov A; Jones B; Lam B; Liu Y; Kaldor S; Stafford J; Hikami K; Uchiyama N; Kawamoto T; Hikichi Y; Matsumoto S; Amano N; Zhang L; Hosfield D; Skene R; Zou H; Cao X; Ichikawa T
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3662-6. PubMed ID: 23664874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.
    Deng Z; Chen G; Liu S; Li Y; Zhong J; Zhang B; Li L; Huang H; Wang Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Nov; 206():112697. PubMed ID: 32814244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
    Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point.
    Ergul M; Bakar-Ates F
    Anticancer Agents Med Chem; 2019; 19(15):1846-1854. PubMed ID: 31244432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.